Abstract: The present invention concerns a gel composition useful for treating or preventing caries of the root which comprises sodium fluoride and an antibacterial agent in concentrations sufficient to retard or prevent caries of the root and a gel carrier. In the most preferred embodiment, the gel composition further comprises preservatives and taste agents and contains a gel carrier which comprises a combination of gum tragacanth, gum arabic and agar-agar.

Abstract: The present invention relates to an aerosol composition free of propellant gas, comprising nitroglycerin as active ingredient. The composition according to the invention is composed of:0.1 to 4% by weight of nitroglycerin,51 to 90% by weight of a C.sub.2-4 aliphatic alcohol (component A),10 to 49% by weight of a polyalkyleneglycol comprising 2 or 3 carbon atoms in the alkylene moiety (component B.sub.1) and/or a C.sub.2-8 alcohol comprising two or three hydroxy groups (component B.sub.2)optionally together with one or more pharmaceutically acceptable carriers and/or diluents.

Abstract: This invention relates to a novel, non-conventional liposome formulation for the sustained release and delivery of steroids. The formulation provides prolonged release of the drug, improved therapeutic ratio, lower toxicity, reduced systemic side effects and is stable for up to three months. The formulation is suitable for sustained delivery of steroid via inhalation, parenteral, intrathecal, intraarticular, topical, ophthalmic, and oral administration.

Abstract: The present invention involves a liposomal agent for treating disseminated fungal infection in an animal. This liposomal agent comprises a variety of polymer antifungal compounds, particularly hamycin. These antifungal compounds are encapsulated within a liposome decreasing toxicity. This liposome is preferably a stable multilamellar vesicle. The method of administration is preferably parenteral, but may be oral or topical.

Abstract: This invention relates to devices useful for the controlled delivery of one or more beneficial agents to an environment of use. More specifically, this invention concerns such devices which are powered by lyotropic liquid crystals. This inventioin also relates to the controlled delivery of one or more beneficial agents to an aqueous environment of use through the use of such lyotropic liquid crystal powered dispensing devices. Also disclosed are methods for the controlled delivery of one or more beneficial agents to an aqueous environment of use which comprise administering to or otherwise placing the devices of this invention in the environment of use.

Abstract: An improved method for selectively targeting a substance either to the parenchymal cells or the non-parenchymal cells of the liver makes use of the property that there are two pathways for uptake of liposomes by the liver: a saturable pathway involving phagocytosis and mediated by the Kupffer cells, and a non-saturable pathway involving pinocytosis and mediated by the parenchymal cells. The substance to be targeted is administered in carrier liposomes having a diameter of less than about 200 nm and a half-life in the circulation of at least about 5 hours as measured at an injection dose of about 30-50 micrograms of lipid per gram of body weight. The substance can be targeted to the parenchymal cells by administering it in carrier liposomes at a liposomal lipid dose expressed in micrograms of lipid per gram of body weight at least equal to a critical liposomal lipid dose, typically about 7 micrograms per gram of body weight to about 10 micrograms per gram of body weight.

Abstract: A method for preparing an edible anion exchange resin delivery system which comprises the steps of coating granules of resin with lecithin. A gelatin frappe is separately prepared and placed into a mixing chamber. The lecithin-coated resin granules are then added to the chamber and mixed together with the frappe. Flavorings can also be added to the mixture and the final blend is then allowed to set-up in a controlled environment for a predetermined period of time.

Abstract: Drug units are targeted to blood clot matter and release blood clot dissolving material for dissolving the blood clot to allow its subsequent removal from the blood vessel in the body of a living being. In a specific embodiment, drug units are formed of antifibrin antibodies and a blood clot dissolving agent encapsulated in a microcontainer or capsule to which such antibody is attached for release at the site of a targeted blood clot in an artery or vein.

Abstract: The therapeutic compositions of this invention comprise one or more porphycene compounds incorporated within liposomes. The method of this invention for treating cancer comprises administering a therapeutically effective amount of a porphycene derivative to a patient, and exposing an affected body area of the patient to a therapeutically sufficient amount of light having a wavelength of from 600 to 950 nm.

Abstract: Aqueous diffusion coating formulations suitable for use on pharmaceutical dosage forms comprising an admixture of an insoluble polymer component of a copolymer of ethylacrylate and methylmethacrylate and as a hydrophilic component the polysaccharide pullulan. When applied to the substrate of choice, said formulations provide coatings exhibiting good mechanical strength and flexibility.

Abstract: A liposome composition which contains between 1-20 mole percent of an amphipathic lipid derivatized with a polyalkylether, as exemplified by phosphatidylethanolamine derivatized with polyethyleneglycol. The derivatized lipid enchances the circulation time of the liposomes severalfold, and this enhancement is achieved with either fluid or membrane-rigidifying liposome components. Also disclosed are methods for delivering a drug for slow release from the bloodstream, and for targeting a selected tissue or cells with liposomes, via the bloodstream.

Abstract: Basic ferric sulphate or hydrated aluminum chloride solution used as a haemostatic agent, is made easier to handle and apply by gelling with colloidal silicon dioxide.

Abstract: The invention relates to the use of an improved carrier or adjuvant to induce a therapeutic response to a weak antigen.

Abstract: Pulmonary administration of a pharmaceutically active substance useful for local or systemic action which comprises, liposomes containing an effective amount of a pharmaceutically active substance, and an amount of alveolar surfactant protein effective to enhance transport of the liposomes across a pulmonary surface.

Abstract: A composition useful in oral immunisation of animals such as poultry comprises dry free-flowing particles each consisting of a solid beadlet of lipid-continuous emulsion containing from about 25% to about 50% by weight water in a lipid, such as hardened palm kernel oil, having a slip point in the range 35.degree. to 45.degree. C., each beadlet having an average diameter of about 2 to 3 millimeters and containing at least 1 viable encysted protozoan, such as a sporulated oocyst of a species of coccidium infective to poultry, each beadlet having a protective coating of animal feed, cement and/or gypsum, the protective coating having an average thickness of about 0.2 to 2 mm.

Abstract: Disclosed are rectal and vaginal suppository formulations comprising calcitonin and caprylic acid monoglyceride in a pharmaceutically acceptable suppository vehicle.

Abstract: The liposome compositions entrapping a drug are prepared by constituting the liposomal membrane with a saturated phospholipid and a glycolipid having sialic acid group. Thus obtained compositions circulate stably in blood for a long time after intravenous administration.

Abstract: A stable oxygen containing dentifrice in powder form which contains a carrier and evenly dispersed therethrough a multiplicity of microencapsulated droplets of an oxygen releasing agent such as hydrogen peroxide. The walls of the microcapsules are rupturable upon mechanical manipulation of the dentifrice as it occurs during the toothbrushing action for releasing the oxygen-containing agent.

Abstract: There is provided a shaving facilitator comprising a composition of pH 5.0-10.0, compounded from a polyethylene oxide polymer (PEOP) a polysulfonic acid polymer (PSAP) and a topically acceptable base. The shaving of hirsute areas of skin is facilitated by applying such a composition to said areas prior to the application of a shaving soap product thereto. Additionally this polymer composition can be incorporated in other, conventional shaving products such as lotions for women's legs and underarms or in aerosol shave foam for use by men and women.

Abstract: The present invention involves a pharmaceutical formulation comprising a liposome having a therapeutically effective concentration of an aromatic polyene macrolide antibiotic. The aromatic polyene macrolide antibiotic usable in the practice of the present invention is selected from the group consisting of candicidin, hamycin, aurefungin, ascosin, ayfattin, azacolutin, DJ400-B, trichomycin, levorin, heptamycin, candimycin or perimycin. The most preferred aromatic polyene macrolide antibiotic is candicidin. An important aspect of the present invention is a method for treating disseminated fungal infection in an animal comprising administering to an animal such as a human a pharmaceutical formulation comprising a liposome having a therapeutically effective amount of aromatic polyene macrolide antibiotic as described above.